Drug Search Results
More Filters [+]

Fasiglifam

Alternative Names: fasiglifam, tak-875
Latest Update: 2024-01-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: FFA1 Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Fasiglifam

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: General Diabetes|Type 2 Diabetes|Kidney Failure, Chronic|Other

Phase 2: General Diabetes|Type 2 Diabetes

Phase 1: Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Comparison of TAK-875 to Glimepiride in Combination with Metformin in Subjects with Type II Diabetes

P3

Terminated

Type 2 Diabetes

2016-01-27

TAK-875_311

P3

Withdrawn

Type 2 Diabetes|Kidney Failure, Chronic

2016-01-01

TAK-875_306

P3

Terminated

Type 2 Diabetes

2014-05-01

TAK-875_302

P3

Terminated

Type 2 Diabetes

2014-03-01

Recent News Events